137 related articles for article (PubMed ID: 25014583)
1. Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia.
Brazzelli V; Grasso V; Elena C; Orlandi E; Borroni G
G Ital Dermatol Venereol; 2015 Oct; 150(5):623-5. PubMed ID: 25014583
[No Abstract] [Full Text] [Related]
2. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
3. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
4. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
Shimizu A; Hattori M; Takeuchi Y; Ishikawa O
J Dermatol; 2016 Sep; 43(9):1100-1. PubMed ID: 27028020
[No Abstract] [Full Text] [Related]
5. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.
Samimi S; Chu E; Seykora J; Loren A; Vittorio C; Rook A; Rosenbach M; Kim EJ
JAMA Dermatol; 2013 May; 149(5):637-9. PubMed ID: 23677113
[No Abstract] [Full Text] [Related]
6. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
7. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
8. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
Hanley B; Nesr G; Yebra-Fernandez E; Brown L; Rabitsch A; Killeen N; Claudiani S; Milojkovic D; Kanfer E; Apperley J; Naresh KN
J Clin Pathol; 2019 Jul; 72(7):511-512. PubMed ID: 31004076
[No Abstract] [Full Text] [Related]
9. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.
Nuno-Gonzalez A; Dehesa L; Ricotti C; Kerdel F
Int J Dermatol; 2014 Apr; 53(4):494-6. PubMed ID: 24262013
[No Abstract] [Full Text] [Related]
11. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
13. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
15. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.
Wang Z; Jiang L; Yan H; Xu Z; Luo P
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):445-456. PubMed ID: 33618586
[No Abstract] [Full Text] [Related]
16. Cardiovascular event in chronic myeloid leukaemia treated with tyrosine kinase inhibitor: a case report.
Boo YL; Liam CCK; Lim SY; Look ML
Hong Kong Med J; 2019 Feb; 25(1):74-5. PubMed ID: 30713145
[No Abstract] [Full Text] [Related]
17. Cutaneous reactions to STI571.
Brouard M; Saurat JH
N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
[No Abstract] [Full Text] [Related]
18. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
[No Abstract] [Full Text] [Related]
19. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
20. Oral lichenoid eruption associated with imatinib treatment.
Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
